The overall sentiment of these big-money traders is split between 36% bullish and 31%, bearish. Out of all of the special options we uncovered, 10 are puts, for a total amount of $724,710, and 12 are ...

Itepekimab (Sanofi/Regeneron Pharmaceuticals), Benralizumab (AstraZeneca), Tezepelumab (Amgen/AstraZeneca), Mepolizumab (GSK), and others shall further create a positive impact on the market.

On June 10, 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price target at $580. REGN is one of the 7 52-week ...